Vulvar cancer is a medical condition associated with abnormal cell growth on the vulva, the external part of the female genitalia, which encompasses the clitoris, labia majora and minora, vaginal opening, and the skin in its vicinity.

1. Vulvar Cancer
Market Research
Report 2023-2033

2. ABOUT IMARC
2
International Market Analysis Research and Consulting Group is a
leading adviser on management strategy and market research
worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific,
economic and technological developments for business leaders in
pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel and tourism,
nanotechnology and novel processing methods are at the top of
the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into
the dynamics of companies and markets with close cooperation at
all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient
organizations, and secure lasting results.

3. Report Description and Highlights
Vulvar Cancer Market 2023-2033
The newly published report by IMARC Group, titled ”Vulvar Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity,
and Forecast 2023-2033″, presents a comprehensive analysis of the vulvar cancer market. The report provides an overview of the market
trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market
scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the seven
major markets (7MM). The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Vulvar Cancer Market Size:
The vulvar cancer market is anticipated to grow at a CAGR of 4.89% during 2023-2033.
Request a Sample Report: https://www.imarcgroup.com/vulvar-cancer-market/requestsample
3

4. Report Description and Highlights
What is vulvar cancer?
Vulvar cancer is a medical condition associated with abnormal cell growth on the vulva, the external part of the female genitalia, which
encompasses the clitoris, labia majora and minora, vaginal opening, and the skin in its vicinity. The proliferation of these abnormal cells can
lead to the formation of malignant tumors. Symptoms linked with this disease include consistent itchiness, pain, sensitivity, a visible lump
or ulcer on the vulva, alterations in skin color or thickness in the afflicted area, as well as non-menstrual bleeding or discharge.
In more severe instances, lymph nodes close to the vulva may become noticeably swollen. The diagnostic procedure for vulvar cancer
generally comprises a thorough clinical assessment, a review of the patient’s medical history, and a physical examination. Healthcare
practitioners may also employ various imaging techniques, including ultrasound, computed tomography scans, and magnetic resonance
imaging, to gauge the extent and stage of cancer.
4

5. Report Description and Highlights
What are the key drivers and trends in the vulvar cancer market?
The growing instances of high-risk human papillomavirus infections that can induce cellular transformations, ultimately leading to the
formation of precancerous lesions, are primarily driving the market growth. Besides this, the expanding older female population
susceptible to hormonal changes, such as a decrease in estrogen levels during menopause, is creating a favorable outlook for market
expansion.
Moreover, the increasing use of radiation therapy, employing high-energy X-rays to reduce tumors pre-surgery and eradicate remaining
cancer cells post-surgery, is presenting remunerative growth opportunities for the market. In addition to this, the rising adoption of
hormonal drug therapies such as tamoxifen and aromatase inhibitors, which function by obstructing estrogen’s effect on cancer cells,
thereby reducing recurrence risks, is aiding in market expansion. Furthermore, the surging interest in targeted therapies designed to inhibit
overexpressed or mutated molecules, consequently preventing tumor growth, is propelling the market forward.
5

6. Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033
Countries Included:
• United States
• Germany
• France
6

7. Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vulvar cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vulvar cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs
7

8. Report Description and Highlights
In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status
View Report TOC, Figures and Tables: https://www.imarcgroup.com/vulvar-cancer-market
8

9. Key Questions Answered in the Report
1. How has the vulvar cancer market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
3. What was the country-wise size of the vulvar cancer market across the seven major markets in 2022 and what will it look like in 2033?
4. What is the growth rate of the vulvar cancer market across the seven major markets and what will be the expected growth over the
next ten years?
5. What are the key unmet needs in the market?
9

10. Table of
Contents

11. Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Vulvar Cancer - Introduction
11

12. Table of Contents
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Vulvar Cancer - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/vulvar-cancer-market/toc
12

13. Partial List Of Our Clients
13

14. OUR CLIENTS
14

15. Disclaimer
15
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis
Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or
in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including
photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information
and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting
makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts
no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and
Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.